Enliven Therapeutics, Inc.
ELVN
$18.27
-$1.42-7.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -0.10% | -16.07% | 12.26% | -17.39% | 6.74% |
| Total Depreciation and Amortization | 0.00% | 2.56% | -1.27% | 1.28% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.69% | 54.28% | -2.85% | 192.20% | -18.18% |
| Change in Net Operating Assets | -110.22% | 213.78% | 5.42% | -184.83% | 73.35% |
| Cash from Operations | -41.09% | 40.33% | 12.53% | -87.16% | 21.47% |
| Capital Expenditure | 100.00% | -1,000.00% | 90.00% | -42.86% | 12.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -95.10% | 144.11% | -88.43% | -146.16% | 208.91% |
| Cash from Investing | -95.10% | 144.04% | -88.23% | -146.23% | 208.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,478.51% | -38.15% | -98.00% | 100,200.00% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 3,478.51% | -38.15% | -98.00% | 100,200.00% | 121.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 526.56% | 107.17% | -206.67% | 86.45% | 150.69% |